Trodelvy plus Keytruda effective for aggressive breast cancer type: Gilead Sciences Ruchika Sharma23 April 2025 10:30 AM ISTFoster City: Gilead Sciences, Inc. has announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that...
Merck discontinues clinical development programs for vibostolimab, favezelimab Ruchika Sharma18 Dec 2024 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for...
Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced Epithelial Ovarian Cancer: Merck Ruchika Sharma11 Dec 2024 5:54 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA...
Merck gets positive EU CHMP opinion for Keytruda plus Chemotherapy as first-line treatment for adult patients with unresectable non-eithelioid Malignant Pleural Mesothelioma Ruchika Sharma19 Nov 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Submit preclinical data in animal and Phase I CT data: CDSCO Panel Tells IQVIA on Pembrolizumab study Dr. Divya Colin2 Nov 2024 6:00 PM ISTNew Delhi: After reviewing the Phase I/III clinical study protocol of the anti-cancer drug Pembrolizumab, the Subject Expert Committee (SEC)...
MSD Phase 3 trial of head and neck cancer treatment meets primary endpoint Ruchika Sharma13 Oct 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA...
Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers Ruchika Sharma24 Sept 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Merck discontinues Phase 3 trial for lung cancer combo drug Ruchika Sharma11 Aug 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the Phase 3 KeyVibe-008 trial based on...
Roche to halt lung cancer treatment trial Ruchika Sharma8 July 2024 5:43 PM ISTBased on these results, patients and investigators will be unblinded and we intend to halt the study.
Merck discontinues Vibostolimab, Pembrolizumab coformulation arm of Phase 3 KeyVibe-010 trial in Melanoma Ruchika Sharma14 May 2024 4:17 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the vibostolimab and pembrolizumab...
Merck gets Canadian nod for Keytruda in combo with fluoropyrimidine- and platinum-containing-chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma Ruchika Sharma23 April 2024 3:08 PM ISTKirkland: Merck, known as MSD outside the United States and Canada, has announced that Health Canada has granted approval of KEYTRUDA...
EMA validates Type II variation application for Padcev with Keytruda for first line treatment of advanced Bladder Cancer: Pfizer Ruchika Sharma28 Jan 2024 10:00 AM ISTTokyo: Astellas Pharma Inc. and Pfizer Inc. have announced that the European Medicines Agency (EMA) has validated for review a Type II...
